CHAIN Biotech and the University of Oxford collaborate to tackle oral vaccine inequality
CHAIN announces a new collaboration with clinical researchers at the University of Oxford to develop superior oral vaccines for infectious diseases Marlow, UK- 22nd of June 2022- FOR IMMEDIATE RELEASE CHAIN Biotechnology and the University of Oxford plan to collaborate on a two-year project to develop a new type of vaccine to immunise against human […]
CHAIN Biotech secures Japan patent
Following successful patent applications in the EU and US, CHAIN have extended their patent territories and claimed delivery of β-hydroxy butyrate (β-HB) to the gastrointestinal (GI) tract in Japan. The patent family (publication number: WO2018055388) ‘Compositions and uses thereof for treating inflammatory diseases and probiotic compositions’ covers genetically engineered bacterial strains to express β-HB in […]
US & EU Patents awarded to UK Biotech
CHAIN has developed a platform technology called CADDTM for oral drug delivery based on living bacteria (known as live biotherapeutics). CADDTM is unique, transformational with broad clinical applicability. US and EU patents describing the use of CADDTM to treat inflammatory bowel disease have recently been granted. Marlow, UK – 7th May 2021 – FOR IMMEDIATE […]
Superior and effective microbiome therapeutics
About us
CHAIN Biotechnology Ltd is a microbiome therapeutics company developing oral immuno-therapies.
Platform
Our Clostridium Assisted Drug Development (CADD™) platform combines precision engineering with a superior host bacterium to effectively deliver therapeutic payloads to the lower gastrointestinal (GI) tract.